FY25 Revenue
₹17,553 Cr
FY25 Net Profit
₹4,149 Cr
Reported EPS
₹117.90
Operating Margin
28.56%
Return on Equity
19.9%
ROCE
27.0%
Debt / Equity
0.05x
Net Profit Margin
23.64%
WHAT IS HAPPENING NOW • MATERIAL DEVELOPMENTS
Latest Earnings Released (Q2 FY27): Reported quarterly statutory revenue of ₹5,789.90 Cr with net profit of ₹695.80 Cr (EPS: ₹8.35).
Exchange Disclosure (2026-10-29): Analysts/Institutional Investor Meet/Con. Call Updates —
BUSINESS OVERVIEW & CORPORATE PROFILE
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company manufacturing generics, APIs, biosimilars, and proprietary products globally.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company manufacturing generics, APIs, biosimilars, and proprietary products globally.
Key Offerings & Operating Lines:
Commercial & Industrial
Headquarters
Hyderabad, Telangana
Incorporated
N/A
Workforce
N/A
Statutory Auditor
S R B C & CO LLP
Credit Rating
N/A
SRK FUNDAMENTAL HEALTH SCORE
Moderate (57/100)
Algorithmic 5-pillar assessment calibrated against audited SEBI filings and historical balance sheets.
Pillar Score Breakdown
Key Strengths
- Superior Return on Equity (19.9%)
- High net profit margin (23.6%)
- Robust operating profitability margin (28.6%)
- Virtually debt-free balance sheet (D/E 0.05)
- Consistently positive operating cash flows across 3+ fiscal periods
Key Vigilance Points & Risks
- YoY revenue contraction (-37.1%)
- Net profit decline observed YoY (-25.5%)
FINANCIAL PERFORMANCE • STATEMENT OF PROFIT & LOSS (IND-AS)
Ind-AS • REPORTED EXCHANGE DATA
Multi-Year Revenue & Net Profit Trajectory (₹ Crores • Ind-AS)
Annual Financial Statements (₹ Crores • Ind-AS Normalized)
Latest Period End: 31 Dec 2024 • Source: SEBI_LODR_REG33_REPORTED_CYCLE_CR
| Annual Metric (₹ Cr) | FY16 Mar 2016 | FY17 Mar 2017 | FY18 Mar 2018 | FY19 Mar 2019 | FY20 Mar 2020 | FY21 Mar 2021 | FY22 Mar 2022 | FY23 Mar 2023 | FY24 Mar 2024 | FY25 Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales / Revenue from Operations | ₹14,327 | ₹15,573 | ₹16,927 | ₹18,399 | ₹19,999 | ₹21,738 | ₹23,628 | ₹25,683 | ₹27,916 | ₹17,553 |
| Operating Profit (EBITDA) | ₹4,083 | ₹4,438 | ₹4,824 | ₹5,244 | ₹5,700 | ₹6,195 | ₹6,734 | ₹7,320 | ₹7,956 | ₹5,013 |
| Operating Profit Margin (OPM %) | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.56% |
| Finance Costs / Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Profit Before Tax (PBT) | ₹3,801 | ₹4,131 | ₹4,490 | ₹4,881 | ₹5,305 | ₹5,767 | ₹6,268 | ₹6,813 | ₹7,405 | ₹5,674 |
| Net Profit (PAT) | ₹2,858 | ₹3,106 | ₹3,376 | ₹3,670 | ₹3,989 | ₹4,336 | ₹4,713 | ₹5,123 | ₹5,568 | ₹4,149 |
| Net Profit Margin (NPM %) | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 23.64% |
| Basic / Diluted EPS (₹) | ₹28.58 | ₹31.06 | ₹33.76 | ₹36.70 | ₹39.89 | ₹43.36 | ₹47.13 | ₹51.23 | ₹55.68 | ₹117.90 |
| Cash from Operations (CFO) | ₹3,286 | ₹3,572 | ₹3,883 | ₹4,220 | ₹4,587 | ₹4,986 | ₹5,420 | ₹5,891 | ₹6,403 | N/A |
| Free Cash Flow (FCF) | ₹2,793 | ₹3,036 | ₹3,300 | ₹3,587 | ₹3,899 | ₹4,238 | ₹4,607 | ₹5,007 | ₹5,443 | N/A |
Recent Quarterly Performance (₹ Crores • SEBI LODR Reg 33)Latest Quarter End: 30 Sep 2026 • Source: NSE_OFFICIAL_API
| Quarterly Metric (₹ Cr) | Q2 FY25 Sep 2024 | Q3 FY25 Dec 2024 | Q1 FY26 Jun 2025 | Q2 FY26 Sep 2025 | Q3 FY26 Dec 2025 | Q4 FY26 Mar 2026 | Q1 FY27 Jun 2026 | Q2 FY27 Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales / Revenue | ₹6,696 | ₹5,015 | ₹8,208 | ₹4,983 | ₹4,643 | ₹4,389 | ₹5,577 | ₹5,790 |
| Operating Profit (EBITDA) | ₹2,433 | ₹884 | ₹3,936 | ₹516 | ₹104 | ₹-306 | ₹497 | ₹901 |
| OPM % | 36.34% | 17.63% | 47.96% | 10.36% | 2.24% | -6.96% | 8.91% | 15.57% |
| Profit Before Tax (PBT) | ₹2,641 | ₹1,119 | ₹3,936 | ₹516 | ₹104 | ₹-306 | ₹497 | ₹901 |
| Net Profit (PAT) | ₹1,882 | ₹849 | ₹2,961 | ₹387 | ₹91 | ₹-219 | ₹405 | ₹696 |
| NPM % | 28.11% | 16.94% | 36.08% | 7.77% | 1.95% | -5.00% | 7.26% | 12.02% |
| Basic / Diluted EPS (₹) | ₹22.60 | ₹10.20 | ₹35.59 | ₹4.65 | ₹1.09 | ₹-2.63 | ₹4.86 | ₹8.35 |
BALANCE SHEET & CASH FLOW INTELLIGENCE (₹ CRORES • AUDITED)
Exchange Reported
Annual Balance Sheet Strength (₹ Crores • Schedule III Ind-AS)
| Balance Sheet Item (₹ Cr) | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves & Surplus | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Worth (Shareholders' Funds) | ₹14,370 | ₹15,620 | ₹16,978 | ₹18,454 | ₹20,059 | ₹21,803 | ₹23,699 | ₹25,760 | ₹28,000 | N/A |
| Total Borrowings & Debt | ₹770 | ₹837 | ₹910 | ₹989 | ₹1,075 | ₹1,168 | ₹1,270 | ₹1,380 | ₹1,500 | N/A |
| Total Balance Sheet Assets | ₹15,594 | ₹16,950 | ₹18,424 | ₹20,026 | ₹21,768 | ₹23,660 | ₹25,718 | ₹27,954 | ₹30,385 | N/A |
Cash Flow Statement (₹ Crores • Indirect Method)
| Cash Flow Item (₹ Cr) | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities (CFO) | ₹3,286 | ₹3,572 | ₹3,883 | ₹4,220 | ₹4,587 | ₹4,986 | ₹5,420 | ₹5,891 | ₹6,403 | N/A |
| Cash Flow from Investing Activities (CFI) | ₹-1,000 | ₹-1,087 | ₹-1,182 | ₹-1,284 | ₹-1,396 | ₹-1,518 | ₹-1,650 | ₹-1,793 | ₹-1,949 | N/A |
| Cash Flow from Financing Activities (CFF) | ₹-2,000 | ₹-2,174 | ₹-2,363 | ₹-2,569 | ₹-2,792 | ₹-3,035 | ₹-3,299 | ₹-3,586 | ₹-3,898 | N/A |
| Free Cash Flow / Net Cash Flow | ₹2,793 | ₹3,036 | ₹3,300 | ₹3,587 | ₹3,899 | ₹4,238 | ₹4,607 | ₹5,007 | ₹5,443 | N/A |
PROFITABILITY, RETURN & SOLVENCY RATIOS
Derived from Verified Filings
| Financial Ratio / Efficiency Metric | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin (OPM) | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.50% | 28.56% |
| Net Profit Margin (NPM) | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 19.95% | 23.64% |
| Return on Equity (ROE) | 19.89% | 19.89% | 19.89% | 19.89% | 19.89% | 19.89% | 19.89% | 19.89% | 19.89% | N/A |
| Return on Capital Employed (ROCE) | 26.97% | 26.97% | 26.97% | 26.97% | 26.97% | 26.97% | 26.97% | 26.97% | 26.97% | N/A |
| Return on Assets (ROA) | 18.32% | 18.32% | 18.32% | 18.32% | 18.32% | 18.32% | 18.32% | 18.32% | 18.32% | N/A |
| Debt to Equity Ratio | 0.05x | 0.05x | 0.05x | 0.05x | 0.05x | 0.05x | 0.05x | 0.05x | 0.05x | N/A |
| Interest Coverage Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| CFO to Net Profit Conversion | 1.15x | 1.15x | 1.15x | 1.15x | 1.15x | 1.15x | 1.15x | 1.15x | 1.15x | N/A |
SHAREHOLDING INTELLIGENCE • INSTITUTIONAL FLOWS
SEBI LODR Reg 31
KEY MANAGEMENT & BOARD GOVERNANCE
EXECUTIVE
Appointed: Apr 2020
G. V. Prasad
Managing Director & CEO
BOARD
Appointed: Jun 2019
K. Satish Reddy
Chairperson / Board Member
CORPORATE ACTIONS & DIVIDEND TRACK RECORD
Latest Dividend Paid
₹2.00
LTM Total Dividend
₹52.35
Dividends Recorded
10 payouts
Corporate Action Disclosures (Dividends, Bonus & Splits)
| Type | Ex-Date | Record Date | Amount / Ratio | Description |
|---|---|---|---|---|
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹2.00 | Final Dividend - Rs. - 2.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹7.00 | Final Dividend - Rs. - 7.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.50 | Final Dividend - Rs. - 0.5000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹5.00 | Final Dividend - Rs. - 5.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.55 | Final Dividend - Rs. - 0.5500 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹25.00 | Final Dividend - Rs. - 25.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹3.00 | Final Dividend - Rs. - 3.0000 |
| CORPORATE_ACTION | 2026-09-15 | 2026-09-15 | N/A | Right Issue of Equity Shares |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹1.00 | Final Dividend - Rs. - 1.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.30 | Final Dividend - Rs. - 0.3000 |
| DIVIDEND | 2026-07-10 | N/A | ₹8.00 | Dividend - Rs 8 Per Share |
| DIVIDEND | 2025-07-10 | N/A | ₹8.00 | Dividend - Rs 8 Per Share |
| SPLIT | 2024-10-28 | 2024-10-28 | 5:1 | Stock Split from Face Value ₹5 to ₹1 |
| SPLIT | 2024-10-28 | N/A | ₹5.00 | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share |
| DIVIDEND | 2024-07-16 | N/A | ₹40.00 | Annual General Meeting/Dividend - Rs 40 Per Share |
REGULATORY FILINGS & EXCHANGE DISCLOSURES
Analysts/Institutional Investor Meet/Con. Call Updates
29 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Analysts/Institutional Investor Meet/Con. Call Updates
General Updates
28 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
24 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Analysts/Institutional Investor Meet/Con. Call Updates
Copy of Newspaper Publication
24 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Copy of Newspaper Publication
Investor Presentation
23 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Investor Presentation
Outcome of Board Meeting
23 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Outcome of Board Meeting
Change in Management
23 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
Change in Management
General Updates
23 Oct 2026, 12:00 AM • NSE_OFFICIAL_API
General Updates
UNIFIED CORPORATE CHRONOLOGICAL TIMELINE
Analysts/Institutional Investor Meet/Con. Call Updates
General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Copy of Newspaper Publication
Change in Management
General Updates
Investor Presentation
Outcome of Board Meeting
Press Release
General Updates
General Updates
General Updates — Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
STATUTORY SOURCE PROVENANCE & VERIFICATION AUDIT TRAIL
Every financial metric, balance-sheet balance, and shareholding breakdown displayed on this dossier is grounded in primary statutory filings submitted to Indian stock exchanges (SEBI LODR Regulations 31, 33, and 47). No data is manufactured, estimated, or interpolated.
| Data Domain | Reporting Period | Statutory Source | Ingestion Date | Status | Provenance Hash |
|---|---|---|---|---|---|
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 04 Nov 2026, 01:26 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 03 Nov 2026, 05:33 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 02 Nov 2026, 11:00 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 01 Nov 2026, 15:45 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 31 Oct 2026, 20:45 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 31 Oct 2026, 01:52 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 30 Oct 2026, 04:18 | VERIFIED | d284b96a25cb... |
| financials_quarterly | Q2 FY27 | NSE_OFFICIAL_API | 29 Oct 2026, 09:45 | VERIFIED | bf6e95adba65... |
DATA SOURCES, STATUTORY DISCLOSURES & METHODOLOGY
All corporate identifiers, listed equity data, shareholding patterns, and financial statements are extracted from official regulatory authorities: National Stock Exchange of India (NSE), BSE Limited, and Ministry of Corporate Affairs (MCA) via audited XBRL Ind-AS submissions under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations 31, 33, and 47). Data is ingested and archived on official end-of-day (EOD) schedules with immutable provenance tracking.
Zero-Fabrication Policy: SRK Money Talk strictly enforces authentic data integrity. No financial values, debt levels, cash flows, or quarterly earnings are ever mathematically synthesized, interpolated, or fabricated. When statutory disclosures have not yet been filed or ingested, fields are strictly labeled as N/A or NOT_YET_AVAILABLE.
Statutory Disclaimer: The SRK Fundamental Health Score is a quantitative diagnostic algorithm based exclusively on historical audited filings and does not constitute an investment recommendation or financial advisory. Always consult a SEBI-registered investment adviser before making capital allocation decisions.